BV100 clinical trials
Also written BV100.
How each study uses BV100 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BV100 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BV100 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Single Centre, Open-label, 2-period Fixed-sequence, Phase I Clinical Study to Evaluate the Effect of BV100 on the Pharmacokinetics of Polymyxin B in Healthy VolunteersRecruitingPhase 1BioVersys SASNCT07580586Written as BV100 (300 mg)
- Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus ComplexRecruitingPhase 3BioVersys SASNCT07326540Written as BV100 (300 mg)
- Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus ComplexNot yet recruitingPhase 2BioVersys AGNCT07431307Written as BV100 with 50 mg polymyxin B plus ceftazidime/avibactam
- A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic ImpairmentCompletedPhase 1BioVersys AGNCT05537142Written as BV100
- PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRABCompletedPhase 2BioVersys AGNCT05685615Written as BV100 plus Polymyxin B
- Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100CompletedPhase 1BioVersys AGNCT05684705Written as BV100
- To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100CompletedPhase 1BioVersys AGNCT05684718Written as BV100 (300 mg)
- A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy ParticipantsCompletedPhase 1BioVersys AGNCT05537090Written as BV100
- Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal ImpairmentCompletedPhase 1BioVersys AGNCT05086107Written as BV100
- Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male SubjectsCompletedPhase 1BioVersys SASNCT05087069Written as BV100
- Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Male SubjectsCompletedPhase 1BioVersys SASNCT04636983Written as BV100